Metformin and cancer mortality
The author analyses recent publications supporting the ability of metformin to decrease the risk of cancer morbidity and mortality in patients with type 2diabetes mellitus. Pre-history of the problem (including the use of biguanides for metabolic rehabilitation of oncological patients), the role of...
Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | article |
| Langue: | EN RU |
| Publié: |
Endocrinology Research Centre
2010
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/05da729af1a04fbb8decb7c01a66bd6a |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
| id |
oai:doaj.org-article:05da729af1a04fbb8decb7c01a66bd6a |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:05da729af1a04fbb8decb7c01a66bd6a2021-11-14T09:00:15ZMetformin and cancer mortality2072-03512072-037810.14341/2072-0351-5491https://doaj.org/article/05da729af1a04fbb8decb7c01a66bd6a2010-09-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/5491https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378The author analyses recent publications supporting the ability of metformin to decrease the risk of cancer morbidity and mortality in patients with type 2diabetes mellitus. Pre-history of the problem (including the use of biguanides for metabolic rehabilitation of oncological patients), the role of DM as a riskfactor of cancer morbidity and mortality, mechanisms and targets of metformin anticancer effects, and potential use of this agent in non-diabetic patientsare discussed. The need for the search of the markers of sensitivity and resistance to metformin to be used in oncological practice is emphasized.Lev Mikhaylovich BershteynEndocrinology Research Centrearticlemetformindiabetes mellitusoncological diseasesNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 13, Iss 3, Pp 66-70 (2010) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN RU |
| topic |
metformin diabetes mellitus oncological diseases Nutritional diseases. Deficiency diseases RC620-627 |
| spellingShingle |
metformin diabetes mellitus oncological diseases Nutritional diseases. Deficiency diseases RC620-627 Lev Mikhaylovich Bershteyn Metformin and cancer mortality |
| description |
The author analyses recent publications supporting the ability of metformin to decrease the risk of cancer morbidity and mortality in patients with type 2diabetes mellitus. Pre-history of the problem (including the use of biguanides for metabolic rehabilitation of oncological patients), the role of DM as a riskfactor of cancer morbidity and mortality, mechanisms and targets of metformin anticancer effects, and potential use of this agent in non-diabetic patientsare discussed. The need for the search of the markers of sensitivity and resistance to metformin to be used in oncological practice is emphasized. |
| format |
article |
| author |
Lev Mikhaylovich Bershteyn |
| author_facet |
Lev Mikhaylovich Bershteyn |
| author_sort |
Lev Mikhaylovich Bershteyn |
| title |
Metformin and cancer mortality |
| title_short |
Metformin and cancer mortality |
| title_full |
Metformin and cancer mortality |
| title_fullStr |
Metformin and cancer mortality |
| title_full_unstemmed |
Metformin and cancer mortality |
| title_sort |
metformin and cancer mortality |
| publisher |
Endocrinology Research Centre |
| publishDate |
2010 |
| url |
https://doaj.org/article/05da729af1a04fbb8decb7c01a66bd6a |
| work_keys_str_mv |
AT levmikhaylovichbershteyn metforminandcancermortality |
| _version_ |
1718429631091048448 |